CollPlant Biotechnologies (CLGN) Current Assets (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Current Assets came in at $6.7 million in Q4 2025, down 99.95% YoY from $13.2 billion in Q4 2024, and down 46.55% on a QoQ basis from $12.6 million in Q2 2025.
CollPlant Biotechnologies (CLGN) Current Assets (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Current Assets data on file, last reported at $6.7 million in Q4 2025.
- Quarterly Current Assets fell 99.95% year-over-year to $6.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.7 million (down 99.95% YoY) and the FY2025 annual result came in at $6.7 million, down 99.95% from the prior year.
- Current Assets fell to $6.7 million in Q4 2025, from $12.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $45087.0 billion in Q4 2021 to a low of $6.7 million in Q4 2025.
- A 5-year average of $2514.2 billion and a median of $45.3 million in 2021 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets soared 794344508.88% — and 2025, when it sank 99.95%.
- Tracing CLGN's Current Assets over 5 years: stood at $45087.0 billion in 2021, then tumbled by 99.93% to $31.7 billion in 2022, then plunged by 99.91% to $28.0 million in 2023, then jumped by 46934.47% to $13.2 billion in 2024, then slumped by 99.95% to $6.7 million in 2025.
- The last three Current Assets figures came in at $6.7 million (Q4 2025), $12.6 million (Q2 2025), and $13.2 billion (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.75 Mn |
| Jun 30, 2025 | 12.62 Mn |
| Dec 31, 2024 | 13.18 Bn |
| Sep 30, 2024 | 16.50 Bn |
| Jun 30, 2024 | 20.34 Mn |
| Mar 31, 2024 | 24.48 Bn |
| Dec 31, 2023 | 28.02 Mn |
| Sep 30, 2023 | 31.21 Bn |
| Jun 30, 2023 | 34.86 Mn |
| Mar 31, 2023 | 29.06 Mn |
| Dec 31, 2022 | 31.66 Bn |
| Sep 30, 2022 | 34.46 Mn |
| Jun 30, 2022 | 38.27 Mn |
| Mar 31, 2022 | 42.62 Mn |
| Dec 31, 2021 | 45,087.00 Bn |
| Sep 30, 2021 | 47.90 Mn |
| Jun 30, 2021 | 49.77 Mn |
| Mar 31, 2021 | 51.47 Bn |
| Dec 31, 2020 | 5.68 Mn |
| Sep 30, 2020 | 7.46 Mn |